These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6692433)

  • 1. Contrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports.
    DeVita VT
    Cancer Treat Rep; 1984 Jan; 68(1):339-40. PubMed ID: 6692433
    [No Abstract]   [Full Text] [Related]  

  • 2. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
    Cancer Treat Rep; 1984 Jan; 68(1):343-56. PubMed ID: 6692435
    [No Abstract]   [Full Text] [Related]  

  • 3. Origins and development of chemotherapy research at the National Cancer Institute.
    Zubrod CG
    Cancer Treat Rep; 1984 Jan; 68(1):9-19. PubMed ID: 6362871
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S; Wittes R
    Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of the report of the 1966 Cancer Chemotherapy Collaborative Program Review Committee.
    Richardson AP
    Cancer Treat Rep; 1984 Jan; 68(1):340-1. PubMed ID: 6692434
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of the National Cancer Institute in drug development.
    Doroshow J
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer problems lead list for potential medical marijuana research studies.
    Smigel K
    J Natl Cancer Inst; 1997 Sep; 89(17):1255. PubMed ID: 9293912
    [No Abstract]   [Full Text] [Related]  

  • 8. The National Cancer Institute's Drug Development Program.
    Schepartz SA
    Prog Clin Biol Res; 1985; 197():73-82. PubMed ID: 4070301
    [No Abstract]   [Full Text] [Related]  

  • 9. Planning combined therapy--the interaction of experimental and clinical studies.
    Carter SK
    Cancer Chemother Rep 2; 1974 Mar; 4(1):3-11. PubMed ID: 4826498
    [No Abstract]   [Full Text] [Related]  

  • 10. Collection and presentation of combination data.
    Mancher RR
    Cancer Chemother Rep 2; 1974 Mar; 4(1):167-80. PubMed ID: 4826496
    [No Abstract]   [Full Text] [Related]  

  • 11. An open letter to cancer researchers.
    Elledge SJ; Hannon GJ
    Science; 2005 Oct; 310(5747):439-41. PubMed ID: 16239460
    [No Abstract]   [Full Text] [Related]  

  • 12. [Present strategy for new drug development in the USA].
    Shimada Y
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():315-24. PubMed ID: 7986110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scientists mine for genetic sources of cancer.
    Vickery K
    Provider; 2004 Feb; 30(2):20-3, 27-8, 33. PubMed ID: 14964916
    [No Abstract]   [Full Text] [Related]  

  • 14. [Past and current problems in tumor research].
    von Wasielewski E; Sedlacek HH
    Dtsch Med Wochenschr; 1986 Apr; 111(16):630-7. PubMed ID: 3956405
    [No Abstract]   [Full Text] [Related]  

  • 15. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some thoughts on the reporting of adverse events in phase II cancer clinical trials.
    Anderson SJ
    J Clin Oncol; 2006 Aug; 24(24):3821-2. PubMed ID: 16921032
    [No Abstract]   [Full Text] [Related]  

  • 17. Open freezer at NCI.
    Science; 1992 Jan; 255(5040):27. PubMed ID: 1553526
    [No Abstract]   [Full Text] [Related]  

  • 18. The NCI Developmental Therapeutics Program.
    Collins JM
    Clin Adv Hematol Oncol; 2006 Apr; 4(4):271-3. PubMed ID: 16728938
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant chemotherapy of breast cancer. Sponsored by the National Cancer Institute, assisted by the Office for Medical Applications of Research, NIH.
    Conn Med; 1980 Nov; 44(11):721-3. PubMed ID: 7226778
    [No Abstract]   [Full Text] [Related]  

  • 20. The preclinical new drug research program of the National Cancer Institute.
    Driscoll JS
    Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.